Cambrian

Cambrian Bio is a biotech company with multiple programs aimed at increasing patients’ healthspan. The company follows a “hub-and-spoke” structure, in which Cambrian functions as the central parent company that finances a network of subsidiary or partner companies developing independent therapeutics. As of December 2025, the company’s lead compound was a small molecule AMPK activator and enhancer of mitochondrial respiration, with the potential to offset side effects of GLP-1 weight loss drugs while promoting cardiac function. Though Cambrian has yet to bring any drugs to the market, its unique company structure helps to decorrelate risk. Should it succeed, Cambrian could establish a scalable blueprint for developing aging-related therapeutics at a time when the field is becoming increasingly scientifically validated, but is still hindered by regulatory uncertainty.